Pfizer Inc. (NYSE:PFE) Shares Sold by Roman Butler Fullerton & Co.

Roman Butler Fullerton & Co. cut its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 29.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 28,127 shares of the biopharmaceutical company's stock after selling 11,684 shares during the period. Roman Butler Fullerton & Co.'s holdings in Pfizer were worth $713,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Pfizer in the 4th quarter valued at about $2,328,986,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares during the period. Starboard Value LP purchased a new position in shares of Pfizer during the fourth quarter worth approximately $407,730,000. Raymond James Financial Inc. acquired a new position in shares of Pfizer in the 4th quarter valued at $274,694,000. Finally, Assenagon Asset Management S.A. raised its position in Pfizer by 307.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock valued at $254,574,000 after purchasing an additional 7,581,030 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

PFE has been the topic of several research reports. UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Cantor Fitzgerald started coverage on Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target for the company. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Stock Performance

Shares of PFE opened at $24.00 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a 50-day simple moving average of $23.14 and a 200-day simple moving average of $24.93. The company has a market capitalization of $136.47 billion, a PE ratio of 17.39, a P/E/G ratio of 0.89 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period in the previous year, the firm earned $0.82 EPS. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.17%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer's payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.